| Economic evaluation of cancer therapies: more and better studies will lead to better choices in cancer care. | |
| | |
MedLine Citation:
|
PMID: 17008095 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Randomised phase III trials are the ideal setting for prospective collection of economic and health related quality of life (HRQL) data. Many studies combine prospective clinical data with economic assumptions or data collected in separate costing studies. To extrapolate the trial outcomes to lifelong consequences, modelling approaches are often used. Also, in situations where no randomised trial data are available, modelling approaches are often applied. In this paper some methodological and practical issues are described. The aim of the economic evaluations is to support decision-making. As many new promising anti cancer drugs are forthcoming, the questions of how decision-makers will use the results of the economic evaluations and how patients can optimally benefit from these new drugs arise. |
| | |
Authors:
|
Carin A Uyl-de Groot |
Related Documents
:
|
4019705 - Determining the duration of comparative clinical trials while allowing for cure. 20473185 - Bayesian meta-analyses for comparative effectiveness and informing coverage decisions. 18999175 - Clinical trials in silico: rigorous assessment of treatment effect using electronic hea... 9160485 - Power considerations for clinical trials using multivariate time-to-event data. 12413145 - Stress assessment by means of questionnaires. 23071215 - Genotype prediction of adult type 2 diabetes from adolescence in a multiracial population. |
Publication Detail:
|
Type: Journal Article; Review Date: 2006-09-27 |
Journal Detail:
|
Title: European journal of cancer (Oxford, England : 1990) Volume: 42 ISSN: 0959-8049 ISO Abbreviation: Eur. J. Cancer Publication Date: 2006 Nov |
Date Detail:
|
Created Date: 2006-11-07 Completed Date: 2007-02-09 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9005373 Medline TA: Eur J Cancer Country: England |
Other Details:
|
Languages: eng Pagination: 2862-6 Citation Subset: IM |
Affiliation:
|
Institute for Medical Technology Assessment, Erasmus MC, University Medical Centre, PO Box 1700, 3000 DR Rotterdam, The Netherlands. c.uyl@erasmusmc.nl <c.uyl@erasmusmc.nl> |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
economics Cost-Benefit Analysis Decision Making Humans Neoplasms / economics*, therapy Randomized Controlled Trials as Topic Risk Assessment Sample Size Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Health technology assessment in cancer: a personal view from public health.
Next Document: Evaluation of a upflow anaerobic sludge blanket reactor with partial recirculation of effluent used ...